Bristol Myers Squibb Terminates Agreements With Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing
Bristol Myers Squibb Terminates Agreements With Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing
On December 12, 2024, Bristol Myers Squibb ("BMS") notified Immatics N.V. (the "Company") that, due to ongoing portfolio prioritization efforts within BMS, it has elected to terminate the collaboration agreement, dated June 1, 2022, between Celgene Switzerland LLC and Immatics US, Inc., relating to the development of allogeneic programs, and the opt-in agreement, dated April 28, 2023, between Celgene Switzerland LLC and Immatics GmbH, relating to a target under the parties' multi-target TCR-T strategic collaboration. The terminations are effective as of March 12, 2025. The Company is not obligated to refund BMS any part of the $60 million upfront payment received under the collaboration agreement or the $15 million opt-in payment received under the opt-in agreement. The Company's collaboration with BMS under the 2019 multi-target TCR-T strategic collaboration agreement remains ongoing.
2024年12月12日，百時美施貴寶（「BMS」）通知Immatics N.V.（「公司」），由於BMS內部正在進行投資組合優先排序，該公司已選擇終止瑞士Celgene LLC與Immatics US, Inc.於2022年6月1日簽訂的與異體項目開發有關的合作協議，以及瑞士Celgene於2023年4月28日簽訂的選擇加入協議有限責任公司和Immatics GmbH，涉及雙方多目標TCR-t戰略合作下的目標。終止自2025年3月12日起生效。公司沒有義務向BMS退還根據合作協議收到的6000萬美元預付款或根據選擇加入協議收到的1500萬美元選擇加入付款中的任何一部分。根據2019年多目標TCR-t戰略合作協議，該公司與BMS的合作仍在進行中。